CO2022019316A2 - Inhibidores alostéricos de egfr y métodos de uso de estos - Google Patents
Inhibidores alostéricos de egfr y métodos de uso de estosInfo
- Publication number
- CO2022019316A2 CO2022019316A2 CONC2022/0019316A CO2022019316A CO2022019316A2 CO 2022019316 A2 CO2022019316 A2 CO 2022019316A2 CO 2022019316 A CO2022019316 A CO 2022019316A CO 2022019316 A2 CO2022019316 A2 CO 2022019316A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- allosteric inhibitors
- egfr
- compounds
- egfr allosteric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036622P | 2020-06-09 | 2020-06-09 | |
| US202063111429P | 2020-11-09 | 2020-11-09 | |
| PCT/US2021/036657 WO2021252661A1 (en) | 2020-06-09 | 2021-06-09 | Allosteric egfr inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022019316A2 true CO2022019316A2 (es) | 2023-01-16 |
Family
ID=78846544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0019316A CO2022019316A2 (es) | 2020-06-09 | 2022-12-30 | Inhibidores alostéricos de egfr y métodos de uso de estos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230212171A1 (https=) |
| EP (1) | EP4161516A4 (https=) |
| JP (3) | JP7785701B2 (https=) |
| KR (1) | KR20230033645A (https=) |
| CN (1) | CN115811977A (https=) |
| AU (1) | AU2021289729A1 (https=) |
| BR (1) | BR112022025139A2 (https=) |
| CA (1) | CA3181982A1 (https=) |
| CO (1) | CO2022019316A2 (https=) |
| EC (1) | ECSP22098041A (https=) |
| IL (1) | IL298935A (https=) |
| JO (1) | JOP20220332A1 (https=) |
| MX (1) | MX2022015739A (https=) |
| NZ (1) | NZ795548A (https=) |
| SA (1) | SA522441639B1 (https=) |
| WO (1) | WO2021252661A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023289368A1 (en) * | 2022-06-21 | 2025-01-16 | Dana-Farber Cancer Institute, Inc. | Fused bicyclic egfr inhibitors and methods of use thereof |
| GB202216962D0 (en) | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005021963A1 (de) * | 2005-05-12 | 2006-11-23 | Aicuris Gmbh & Co. Kg | Substituierte Dihydropyrazolotriazinone |
| US8163779B2 (en) * | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
| CA2684633A1 (en) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
| JP5746032B2 (ja) * | 2008-09-19 | 2015-07-08 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | ３，４−ジヒドロ−２Ｈ−ピロロ［１，２−ａ］ピラジン−１−オン誘導体 |
| JP6845165B2 (ja) * | 2015-06-30 | 2021-03-17 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｅｇｆｒ阻害剤およびその使用方法 |
| PE20211388A1 (es) * | 2018-06-29 | 2021-07-27 | Hoffmann La Roche | Compuestos |
| JP7086272B2 (ja) * | 2018-08-16 | 2022-06-17 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | イソインドリン－１－オン誘導体、同じものを調製する方法、およびがんを予防するまたは処置するための有効な構成要素として同じものを含む医薬組成物 |
-
2021
- 2021-06-09 US US18/000,722 patent/US20230212171A1/en active Pending
- 2021-06-09 NZ NZ795548A patent/NZ795548A/en unknown
- 2021-06-09 AU AU2021289729A patent/AU2021289729A1/en active Pending
- 2021-06-09 CA CA3181982A patent/CA3181982A1/en active Pending
- 2021-06-09 IL IL298935A patent/IL298935A/en unknown
- 2021-06-09 BR BR112022025139A patent/BR112022025139A2/pt unknown
- 2021-06-09 EP EP21821203.3A patent/EP4161516A4/en active Pending
- 2021-06-09 KR KR1020227043942A patent/KR20230033645A/ko active Pending
- 2021-06-09 JP JP2022576178A patent/JP7785701B2/ja active Active
- 2021-06-09 WO PCT/US2021/036657 patent/WO2021252661A1/en not_active Ceased
- 2021-06-09 MX MX2022015739A patent/MX2022015739A/es unknown
- 2021-06-09 CN CN202180041075.2A patent/CN115811977A/zh active Pending
-
2022
- 2022-12-07 SA SA522441639A patent/SA522441639B1/ar unknown
- 2022-12-08 JO JOJO/P/2022/0332A patent/JOP20220332A1/ar unknown
- 2022-12-28 EC ECSENADI202298041A patent/ECSP22098041A/es unknown
- 2022-12-30 CO CONC2022/0019316A patent/CO2022019316A2/es unknown
-
2025
- 2025-08-20 JP JP2025137144A patent/JP2025168374A/ja active Pending
- 2025-08-20 JP JP2025137145A patent/JP2025170326A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3181982A1 (en) | 2021-12-16 |
| SA522441639B1 (ar) | 2024-10-24 |
| KR20230033645A (ko) | 2023-03-08 |
| WO2021252661A1 (en) | 2021-12-16 |
| ECSP22098041A (es) | 2023-06-30 |
| IL298935A (en) | 2023-02-01 |
| MX2022015739A (es) | 2023-03-23 |
| JP7785701B2 (ja) | 2025-12-15 |
| NZ795548A (en) | 2026-01-30 |
| US20230212171A1 (en) | 2023-07-06 |
| JP2025170326A (ja) | 2025-11-18 |
| JOP20220332A1 (ar) | 2022-12-08 |
| EP4161516A4 (en) | 2024-08-07 |
| EP4161516A1 (en) | 2023-04-12 |
| JP2025168374A (ja) | 2025-11-07 |
| BR112022025139A2 (pt) | 2023-02-14 |
| CN115811977A (zh) | 2023-03-17 |
| JP2023529701A (ja) | 2023-07-11 |
| AU2021289729A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022019316A2 (es) | Inhibidores alostéricos de egfr y métodos de uso de estos | |
| MX2025000271A (es) | Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2022006466A2 (es) | Inhibidores de egfr alostéricos y métodos de uso de los mismos | |
| UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| CL2022000998A1 (es) | Inhibidores de las cinasas raf | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
| CO2022018806A2 (es) | Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos | |
| CL2022000005A1 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
| DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| BR112023000654A2 (pt) | Composto de pirazolopirimidina usado como inibidor de atr quinase | |
| CL2023002633A1 (es) | Derivados de uracilo como inhibidores de trpa1 | |
| UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| CO2024009144A2 (es) | Inhibidores de cinasa met | |
| CO2025016647A2 (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| CL2025002032A1 (es) | Inhibidores del egfr selectivos de mutantes | |
| CO2022017969A2 (es) | Compuestos de imidazopiridazina con actividad como inhibidores de alk2 | |
| CL2022001377A1 (es) | Compuestos agonistas de tlr7, composiciones y uso para tratar cáncer y enfermedades infecciosas. | |
| DOP2025000274A (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| AR122550A1 (es) | Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblatos | |
| CR20150593A (es) | Potenciador de inhibidores del homólogo de zeste |